Neuroscientific Biopharmaceuticals Ltd (NSB) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.029x

Based on the latest financial reports, Neuroscientific Biopharmaceuticals Ltd (NSB) has a cash flow conversion efficiency ratio of -0.029x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-480.55K ≈ $-340.02K USD) by net assets (AU$16.81 Million ≈ $11.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Neuroscientific Biopharmaceuticals Ltd (NSB) defensive interval to measure how many days the company can operate on defensive assets alone.

Neuroscientific Biopharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Neuroscientific Biopharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Neuroscientific Biopharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Neuroscientific Biopharmaceuticals Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Evion Group NL AU:EVG	-0.122x
ELL ENVIRON.HLDGS HD-0001 F:6EL	N/A
Swvl Holdings Corp NASDAQ:SWVL	-0.177x
Viva Gold Corp V:VAU	-0.063x
N.C. Housing Public Company Limited BK:NCH	0.024x
Shinjin Sm Co.Ltd KQ:138070	0.021x
Macompta Fr Sa PA:MLMCA	N/A
Karya Bersama Anugerah Pt JK:KBAG	0.009x

Annual Cash Flow Conversion Efficiency for Neuroscientific Biopharmaceuticals Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Neuroscientific Biopharmaceuticals Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see NSB market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$16.81 Million ≈ $11.90 Million	AU$-941.33K ≈ $-666.05K	-0.056x	-776.94%
2024-06-30	AU$5.35 Million ≈ $3.79 Million	AU$44.25K ≈ $31.31K	0.008x	+101.68%
2023-06-30	AU$4.69 Million ≈ $3.32 Million	AU$-2.30 Million ≈ $-1.63 Million	-0.491x	+60.97%
2022-06-30	AU$5.52 Million ≈ $3.91 Million	AU$-6.94 Million ≈ $-4.91 Million	-1.258x	-606.05%
2021-06-30	AU$14.60 Million ≈ $10.33 Million	AU$-2.60 Million ≈ $-1.84 Million	-0.178x	+71.50%
2020-06-30	AU$3.65 Million ≈ $2.58 Million	AU$-2.28 Million ≈ $-1.61 Million	-0.625x	-124.79%
2019-06-30	AU$5.06 Million ≈ $3.58 Million	AU$-1.41 Million ≈ $-995.83K	-0.278x	+59.09%
2018-06-30	AU$732.52K ≈ $518.30K	AU$-497.91K ≈ $-352.30K	-0.680x	-95.36%
2017-06-30	AU$535.79K ≈ $379.10K	AU$-186.42K ≈ $-131.90K	-0.348x	+50.65%
2016-06-30	AU$124.47K ≈ $88.07K	AU$-87.76K ≈ $-62.09K	-0.705x	--

About Neuroscientific Biopharmaceuticals Ltd

AU:NSB Australia Biotechnology

Market Cap

$15.53 Million

AU$21.95 Million AUD

Market Cap Rank

#25904 Global

#1160 in Australia

Share Price

AU$0.07

Change (1 day)

+0.00%

52-Week Range

AU$0.06 - AU$0.25

All Time High

AU$0.52